Microalbuminuria: How informative and reliable are individual measurements?

Journal of Hypertension

Volumn 21, Issue 7, 2003, Pages 1229-1233

  Donnelly, Richard ^a,b   Rea, Rustam ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; DIABETES MELLITUS; EDITORIAL; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; MICROALBUMINURIA; OBESITY; PRIORITY JOURNAL; PROGNOSIS; ALBUMINURIA; CLINICAL CHEMISTRY; NOTE; RENOVASCULAR HYPERTENSION; REPRODUCIBILITY; STANDARD;

ALBUMINURIA; CHEMISTRY, CLINICAL; HUMANS; HYPERTENSION, RENAL; REPRODUCIBILITY OF RESULTS;

EID: 0042267960     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200307000-00003     Document Type: Editorial

References (45)

1. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33:1004-1010.
2. Mann JFE, Gerstein HC, Yi Q-L, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14:641-647.
3. Stehouwer CDA, Gall M-A, Twisk JWR, Knudsen E, Emeis JJ, Parving H-H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 2002; 51:1157-1165.
4. Gerstein HC, Mann JFE, Yi Q, Zinman B, Dineen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286:421-426.
5. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20:353-355.
6. Hillege HL, Janssen WMT, Bak AA, Diercks GFH, Grobbec DE, Crijns HJGM, et al. Microalbuminuria is common, also in nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Int Med 2001; 249:519-526.
7. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 1:1190-1192.
8. Redon J, Pascual JM, Miralles A, Sanz C, Gutierrez M, Ros MJ, et al. Microalbuminuria in essential hypertension. Med Clin (Barc) 1991; 96:525-529.
9. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology and therapeutic implications. Am J Kidney Dis 1999; 34:973-995.
10. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent test strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:180-184.
11. Rodicio J, Campo C, Ruilope L. Microalbuminuria in essential hypertension. Kidney Int 1998; 54:S51-S54.
12. Pedrinelli R, Dell'Omo G, Penno G, Bandinelli S, Bertini A, Di Bello MM. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35:48-54.
13. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Battlo M. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797-805.
14. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. The relationship between blood pressure and urinary albumin excretion in the development of microalbuminuria. Diabetes 1990; 39:245-249.
15. Hoq S, Chen W, Srinivasan SR, Berenson GS. Childhood blood pressure predicts adult microalbuminuria in African Americans, but not in whites: the Bogolusa Heart Study. Am J Hypertens 2002; 15:1036-1041.
16. Pedrinelli R, Bello VD, Catapano G, Talarico L, Materazzi F, Santor GC, et al. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinaemia in nondiabetic atherosclerotic patients. Arterioscler Thromb 1993; 13:900-906.
17. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DJ, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in Nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes 1998; 47:793-800.
18. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension 1994; 23:195-199.
19. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in Nondiabetic subjects. Lancet 1988; 2:530-533.
20. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria and risk of ischaemic heart disease. Hypertension 2000; 35:898-903.
21. Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, Grobbee DE, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large nondiabetic population. Eur Heart J 2000; 21:1922-1927.
22. Bianchi S, Bigazzi R, Amoroso A, Campese VM. Silent ischaemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. J Hum Hypertens 2003; 17:13-20.
23. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9:827-833.
24. Ravera M, Ratto E, Vettoretti S, Viazzi F, Leoncini G, Parodi D, et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 2002; 15:519-524.
25. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21:000-000.
26. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard E, Eiskjaer H, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572-581.
27. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.
28. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25:107-112.
29. Bashyam MM, O'Sullivan NJ, Baker HH, Duggan PF, Mitchell TH. Microalbuminuria in NIDDM. Diabetes Care 1993; 16:634-635.
30. Tiu SC, Lee SS, Cheng MW. Comparison of six commercial techniques in the measurement of microalbuminuria in diabetic patients. Diabetes Care 1993; 16:616-620.
31. Colwell M, Halsey JF. High incidence of false-positive albuminuria results with the MicroBumintest. Clin Chem 1989; 35:1252-1254.
32. Al-Kassab AS. Evaluation of a simple method for the screening of microalbuminuria in diabetic patients. Scand J Clin Lab Invest 1990; 50:913-915.
33. University of York. Complications of Diabetes: renal disease and promotion of self-management. Effect Health Care 2000; 6:1-12.
34. Hutchison AS, O'Reilly DS, MacCuish AC. Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clin Chem 1988; 34:2019-2021.
35. Sawicki PT, Heinemann L, Berger M. Comparison of methods for determination of microalbuminuria in diabetic patients. Diabetic Med 1989; 6:412-415.
36. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in NIDDM: a systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418.
37. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333.
38. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischaemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19:1992-1997.
39. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol 1999; 19:617-624.
40. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol 1997; 80:164-169.
41. Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata PAC. Target organ damage in stage 1 hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998; 31:57-63.
42. Agewall S, Wikstrand J, Ijungman S, Herlitz H, Fagerberg B, for the Risk Factor Intervention Study Group. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Am J Hypertens 1995; 8:337-342.
43. Stehouwer CDA, Yudkin JS, Fioretto P, Nosadini R. How heterogeneous is microalbuminuria in diabetes mellitus? The case for 'benign' and 'malignant' microalbuminuria. Nephrol Dial Transplant 1998; 13: 2751-2754.
44. Greaves M, Malia RG, Goodfellow K, Mattock M, Stevens LK, Stephenson JM, et al. Fibrinogen and von Willibrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM complications study. Diabetologia 1997; 40:698-705.
45. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabetic Med 1999; 16:219-227.